Alnylam Pharmace. buy stratec
Summary
This prediction ended on 05.11.21 with a price of €159.80. With a performance of 42.01% the BUY prediction by stratec was a big success. stratec has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -3.946% | -3.946% | -25.843% | 17.551% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |
Comments by stratec for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam with its first new drug application and multiple clinical read-outs in 2018
Alnylam Pharmaceuticals (NASDAQ:ALNY) an Out of the Gate 2018 Pick at B. Riley FBR with a $205 (65% upside) price target citing expected positive FDA decision on patisiran in hATTR in July and expected positive Phase 3 data in porphyria (ENVISION study).
Alnylam had an active 2017, with its first new drug application (or NDA) submitted to the FDA and multiple clinical read-outs, and 2018 is likely to be no less busy. This new year should see the company get its first FDA approval and begin its first commercial launch, in additional to more incremental data on several programs, including data that could potentially support an NDA filing for givosiran before year-end. Moreover, management has not been shy about leveraging good news to raise funds, leaving the company with close to $1.7 billion in cash to start the year.
In the thread Trading Alnylam Pharmace.